Upgrade to SI Premium - Free Trial

Neurocrine Bio. (NBIX) PT Raised to $185 at Morgan Stanley

April 10, 2026 6:06 AM
Morgan Stanley analyst Jeffrey Hung raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $185.00 (from $173.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change